Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eupraxia PharmaceuticalsEPRX -0.15%34 3-1 Month Momentum % is -9.84% as of Aug. 05, 2026. GuruFocus rates EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 53.16% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-05), Eupraxia Pharmaceuticals's 3-1 Month Momentum % is -9.84%.
The industry rank for Eupraxia Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
EPRX's 3-1 Month Momentum % is ranked better than 53.16% of 1394
companies
in the Biotechnology industry
Industry Median: -6.89
vs EPRX: -9.84
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Eupraxia Pharmaceuticals 3-1 Month Momentum % Related Terms
EPRX vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eupraxia Pharmaceuticals (EPRX) has a 3-1 Month Momentum % of -9.84% as of Aug. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Eupraxia Pharmaceuticals and its competitors. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #653 out of 1394 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Eupraxia Pharmaceuticals' 3-1 Month Momentum % too high?
Eupraxia Pharmaceuticals' current 3-1 Month Momentum % is -9.84%. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #653 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #653 out of 1394 companies for 3-1 Month Momentum %. This puts Eupraxia Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current 3-1 Month Momentum % is -9.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (EPRX) has a current 3-1 Month Momentum % of -9.84%. The current 3-1 Month Momentum % is -9.84%. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (EPRX), the current 3-1 Month Momentum % is -9.84% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score
Get the complete analysis for EPRX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPRX has been successfully added to your 
